KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) EBT (2016 - 2025)

Johnson & Johnson (JNJ) has disclosed EBT for 17 consecutive years, with $5.0 billion as the latest value for Q4 2025.

  • Quarterly EBT rose 27.76% to $5.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.6 billion through Dec 2025, up 95.25% year-over-year, with the annual reading at $32.6 billion for FY2025, 95.25% up from the prior year.
  • EBT hit $5.0 billion in Q4 2025 for Johnson & Johnson, down from $7.5 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $13.6 billion in Q1 2025 to a low of -$1.3 billion in Q2 2023.
  • Historically, EBT has averaged $5.2 billion across 5 years, with a median of $5.2 billion in 2022.
  • Biggest five-year swings in EBT: tumbled 124.74% in 2023 and later soared 388.58% in 2024.
  • Year by year, EBT stood at $3.8 billion in 2021, then skyrocketed by 34.37% to $5.2 billion in 2022, then fell by 6.69% to $4.8 billion in 2023, then fell by 19.46% to $3.9 billion in 2024, then rose by 27.76% to $5.0 billion in 2025.
  • Business Quant data shows EBT for JNJ at $5.0 billion in Q4 2025, $7.5 billion in Q3 2025, and $6.5 billion in Q2 2025.